Since its introduction in 2019, brolucizumab’s safety has been called into question due to numerous reports of IOI following intravitreal injections [1]. In 2020, post-marketing data showed that there was a confirmed safety alarm of severe ocular adverse events such as retinal vasculitis, and retinal vascular occlusion that may lead to severe visual acuity loss. These events were reported at rates of 3.61 and 2.35 per 10,000 injections, respectively [1]. New concerns have been raised by Thangamathesvaran et al. on intraocular inflammation (IOI) after intravitreal faricimab (Vabysmo) [2]. Therefore, investigating underlying risk factors for IOI development following faricimab would enhance our understanding of this safety concern and inform clinical decision-making.
Many hypothesized causes, including patient susceptibility, the manufacturing process, and agent characteristics, are responsible for the IOI development after intravitreal injections [2]. The manufacturing process of faricimab may induce IOI through protein aggregates of the injection that could release silicone oil from syringes, causing IOI [3]. The Manufacturer and User Facility Device Experience (MAUDE) database of the US Food and Drug Administration (FDA) is a publicly available database representing reports of adverse events involving medical devices [4]. Herein, we aimed to share that we observed a growing number of monthly reports about similar manufacturing concerns related to faricimab which may support that handling and delivery problems could be a main risk factor of IOI.
A targeted search in MAUDE database using the terms “Faricimab” and “Vabysmo” yielded 8 reports, with the initial one recorded on October 16, 2023 (Table 1). Among these, seven reports highlighted concerns related to sterility and contamination issues associated with the needle filter. These issues included the presence of foreign substances, a faulty filter needle that fractured during vial insertion, leading to drug leakage, a complaint about a fiber wrapped around the filter needle, and a case where the stopper of the filter needle was found positioned ‘way up the middle’ of the filter needle. Furthermore, a separate incident was reported where the needle fell apart before administration. Notably, most reports were identified before any ocular manifestations. In contrast, two reports highlighted patients experiencing IOI; one was endophthalmitis and the other was not specified.
In conclusion, manufacturer and handling issues may overstate the challenges and adverse events following faricimab. Prospective monitoring and surveillance system reporting are required in the future to discover potential concerns before they cause health issues or repercussions.
Data availability
All the data used in this study are available within the article.
References
Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20:100989.
Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, et al. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024;142:365–70.
Melo GB, Figueira ACM, Batista FAH, Filho AASL, Rodrigues EB, Belfort R Jr, et al. Inflammatory reaction after aflibercept intravitreal injections associated with silicone oil droplets released from syringes: a case-control study. Ophthalmic Surg Lasers Imaging Retin. 2019;50:288–94.
Manufacturer and User Facility Device Experience. 2024 [cited 2024 09/03/2024]; Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm.
Acknowledgments
Qatar National Library funded the publication of this article.
Funding
No funding was received for this research. Open Access funding provided by the Qatar National Library.
Author information
Authors and Affiliations
Contributions
IMA and HAS have made considerable contributions in the conception and design of the study, in the acquisition, analysis, and interpretation of the data, and in the drafting of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Alkhawaldeh, I.M., Abu Serhan, H. Intraocular Inflammation with faricimab: insights from Manufacturer and User Facility Device Experience (MAUDE) database. Eye (2024). https://doi.org/10.1038/s41433-024-03079-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03079-0